We are Fulfilling Unmet Needs in Pulmonary Medicine.

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.

Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:

• Continued development of proprietary respiratory disease therapies

• Pursue regulatory pathways that reduce the time, costs and risks associated with product development

• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing

• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States

• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise

News & Events

Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis Presentation
[22MAY17]

Aradigm Announces First Quarter 2017 Financial Results
[05MAY17]

Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results
[31MAR17]

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13
[09FEB17]

2017 BIO CEO & Investor Conference Webcast

2017 BIO CEO & Investor Conference Presentation

More News >>